Jill is a Partner with SR One based on the East Coast. Jill’s educational background is in biochemistry and her career has spanned 20 years in various facets of the biotechnology industry. Initially, she spent time in strategy consulting focusing on commercial projects with pharma, then migrated to operating roles in corporate development, particularly at Dynavax Technologies (DVAX), where she completed multiple pharma partnerships and private and public financings. Jill started her investing career at SR One in 2011 and has been involved in marquee investments including Alios Biopharma, Progyny (PGNY) and Principia Biopharma (PRNB), among others.
Jill received a BS in chemistry from Duke University and a MS in Biochemistry, Cellular and Molecular Biology from Johns Hopkins University
At SR One, we are laser focused on generating clinical proof of concept with new medicines that aim to address the most critical needs of patients. By partnering with top entrepreneurs, we work with our portfolio companies to create new paradigms in medicine.